← All trials
NCT05479370
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Jul 29, 2022
- Last posted
- Oct 27, 2022
- Enrollment
- 360
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanyang Technological UniversityLead sponsor
- A*StarCollaborator
- National Center for Infectious DiseasesOverall official - principal investigator
- SanofiCollaborator
- Nanyang Technological UniversityReponsible party - principal investigator
- Nanyang Technological UniversitySponsor investigator
- National Center for Infectious DiseasesOfficial
- University of MelbourneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.